Danske Bank A S Makes New Investment in Elevance Health, Inc. $ELV

Danske Bank A S purchased a new stake in Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 115,518 shares of the company’s stock, valued at approximately $37,326,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its stake in shares of Elevance Health by 3.6% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 48,555 shares of the company’s stock valued at $18,887,000 after acquiring an additional 1,676 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Elevance Health by 5.7% during the second quarter. Nomura Asset Management Co. Ltd. now owns 82,011 shares of the company’s stock worth $31,899,000 after acquiring an additional 4,405 shares in the last quarter. Pinnacle Wealth Planning Services Inc. grew its holdings in Elevance Health by 23.0% in the second quarter. Pinnacle Wealth Planning Services Inc. now owns 920 shares of the company’s stock worth $358,000 after purchasing an additional 172 shares during the period. Vanguard Group Inc. grew its holdings in Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after purchasing an additional 704,790 shares during the period. Finally, Perennial Investment Advisors LLC increased its stake in Elevance Health by 37.9% in the second quarter. Perennial Investment Advisors LLC now owns 644 shares of the company’s stock valued at $251,000 after purchasing an additional 177 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Down 0.3%

ELV opened at $294.98 on Thursday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market capitalization of $65.10 billion, a P/E ratio of 11.74, a PEG ratio of 1.62 and a beta of 0.51. The company’s 50-day moving average is $333.87 and its 200 day moving average is $333.89. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter last year, the business posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.3%. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Analyst Ratings Changes

Several brokerages have recently weighed in on ELV. UBS Group set a $400.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. Truist Financial dropped their price target on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Robert W. Baird increased their price target on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.